Medical News

RSS

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

OneWorld Health (OWH), a nonprofit that develops lifesaving medicines for neglected diseases, announced that it has signed a nonexclusive patent agreement with Eisai Co., Ltd., for a water-soluble pro-drug technology patent. OWH will use the pro-drug technology to advance development of iOWH032, its new drug to treat acute secretory diarrhea.

2 Apr 2012

Democrats offer optimistic take on court's health law decision

Appearing on the Sunday talk shows, Vice President Joseph Biden and Sen. Charles Schumer, D-N.Y., defended the health law and predicted it would be upheld by the high court.

2 Apr 2012

Biotage adds Isolera Spektra to Flash Chromatography product line

Biotage, a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra. The new Isolera Spektra expands the scope of application of Biotage's market-leading Flash Chromatography product line by increasing efficiency with significant solvent and time saving capabilities as well as enabling purity assessment technology.

2 Apr 2012

Teva reports successful outcome of three debut financings

Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.

2 Apr 2012

Sleep enhances emotionally positive memories

Sleep plays a powerful role in preserving our memories. But while recent research shows that wakefulness may cloud memories of negative or traumatic events, a new study has found that wakefulness also degrades positive memories. Sleep, it seems, protects positive memories just as it does negative ones, and that has important implications for the treatment of post-traumatic stress disorder.

2 Apr 2012

Political cartoon: 'Second Guessing?'

Kaiser Health News provides a fresh take on health policy developments with "Second Guessing?" by Mike Smith.

2 Apr 2012

Rare T follicular helper cells essential for developing antibody responses to infectious agents

The characterisation of a rare immune cell's involvement in antibody production and ability to 'remember' infectious agents could help to improve vaccination and lead to new treatments for immune disorders, say researchers from the Walter and Eliza Hall Institute.

2 Apr 2012

Targeting inflammatory pathways may lead to new therapies

Scientists at Fox Chase Cancer Center have uncovered more details about how defects in components of the machinery that makes new proteins can lead to blood and other cancers.

2 Apr 2012

New York Times examines global response to Haiti's cholera epidemic

The New York Times examines the global response to Haiti's cholera epidemic, writing that while "[m]any health officials consider the cholera response 'pretty remarkable,' as John Vertefeuille, the Centers for Disease Control and Prevention's director in Haiti, said ... [o]thers ... believe the bar for success was set too low and more lives could have been saved."

2 Apr 2012

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company's AIGISRx Antibacterial Envelope.

2 Apr 2012

ulrich medical releases enhancements to spinal implant portfolio

ulrich medical USA, Inc. today announced the release of two important product line enhancements to their growing spinal implant portfolio of expandable cage technologies.

2 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

Study sheds light on cellular mechanisms involved in flu resistance

Scientists from the University of Utah School of Medicine have discovered that a mouse protein called IFITM3 contributes to the body's defense against some types of viral infections by binding to an enzyme responsible for regulating the pH of a cell's waste disposal system.

2 Apr 2012

Linkwell to acquire Metamining Nevada

Linkwell Corporation, a developer, manufacturer and distributer of disinfectant healthcare products in China, announced today it has entered into a definitive share exchange agreement with Metamining Inc. to acquire Metamining Nevada, Inc., as a wholly owned subsidiary,

2 Apr 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

AlloCure closes $25 million Series B venture financing

AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing.

2 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012

Accountable Healthcare completes acquisition of MED-STAFF Oklahoma

Accountable Healthcare Holdings Corp, a provider of quality healthcare staffing solutions, today announced that it completed the acquisition of Tulsa, Oklahoma based MED-STAFF Oklahoma, a predominately Travel Nurse focused business that specializes in placing registered nurses, physical and occupational therapists and diagnostic imaging techs in all fifty U.S. states.

2 Apr 2012